BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Meadows KL, Hurwitz HI. Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med 2012;2:a006577. [PMID: 23028128 DOI: 10.1101/cshperspect.a006577] [Cited by in Crossref: 132] [Cited by in F6Publishing: 123] [Article Influence: 14.7] [Reference Citation Analysis]
Number Citing Articles
1 Hultgren NW, Fang JS, Ziegler ME, Ramirez RN, Phan DTT, Hatch MMS, Welch-Reardon KM, Paniagua AE, Kim LS, Shon NN, Williams DS, Mortazavi A, Hughes CCW. Slug regulates the Dll4-Notch-VEGFR2 axis to control endothelial cell activation and angiogenesis. Nat Commun 2020;11:5400. [PMID: 33106502 DOI: 10.1038/s41467-020-18633-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
2 Failla CM, De Luca N, Zaccaria ML, De Domenico E, Avitabile S, Tatangelo L, Rossiter H, Tschachler E, Odorisio T. Mice over-expressing placenta growth factor in the skin exhibit increased vascularization and vessel permeability independently of VEGF-A. J Dermatol Sci 2018;90:93-6. [PMID: 29366525 DOI: 10.1016/j.jdermsci.2017.12.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Lütje S, Rijpkema M, Helfrich W, Oyen WJG, Boerman OC. Targeted Radionuclide and Fluorescence Dual-modality Imaging of Cancer: Preclinical Advances and Clinical Translation. Mol Imaging Biol 2014;16:747-55. [DOI: 10.1007/s11307-014-0747-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
4 Trautmann A. From kinetics and cellular cooperations to cancer immunotherapies. Oncotarget 2016;7:44779-89. [PMID: 27014912 DOI: 10.18632/oncotarget.8242] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
5 Tsai CY, Su CH, Leu S, Chang AY, Chan JY, Chan SH. Endogenous vascular endothelial growth factor produces tonic facilitation of cardiac vagal baroreflex via fetal liver kinase-1 in medulla oblongata. Int J Cardiol 2015;187:421-5. [PMID: 25841140 DOI: 10.1016/j.ijcard.2015.03.375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
6 Kumar V, Yadavilli S, Kannan R. A review on RNAi therapy for NSCLC: Opportunities and challenges. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021;13:e1677. [PMID: 33174364 DOI: 10.1002/wnan.1677] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Dupont CA, Riegel K, Pompaiah M, Juhl H, Rajalingam K. Druggable genome and precision medicine in cancer: current challenges. FEBS J 2021. [PMID: 33626231 DOI: 10.1111/febs.15788] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Kapadia CH, Perry JL, Tian S, Luft JC, Desimone JM. Nanoparticulate immunotherapy for cancer. Journal of Controlled Release 2015;219:167-80. [DOI: 10.1016/j.jconrel.2015.09.062] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 8.8] [Reference Citation Analysis]
9 Panagopoulos V, Zinonos I, Leach DA, Hay SJ, Liapis V, Zysk A, Ingman WV, DeNichilo MO, Evdokiou A. Uncovering a new role for peroxidase enzymes as drivers of angiogenesis. Int J Biochem Cell Biol 2015;68:128-38. [PMID: 26386352 DOI: 10.1016/j.biocel.2015.09.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
10 Moreo A, Vallerio P, Ricotta R, Stucchi M, Pozzi M, Musca F, Meani P, Maloberti A, Facchetti R, Di Bella S, Giganti MO, Sartore-Bianchi A, Siena S, Mancia G, Giannattasio C. Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System. Am J Hypertens 2016;29:158-62. [PMID: 26031304 DOI: 10.1093/ajh/hpv077] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
11 Shan X, Yu W, Ni X, Xu T, Lei C, Liu Z, Hu X, Zhang Y, Cai B, Wang B. Effect of Chitosan Magnetic Nanoparticles Loaded with Ang2-siRNA Plasmids on the Growth of Melanoma Xenografts in Nude Mice. Cancer Manag Res 2020;12:7475-85. [PMID: 32904466 DOI: 10.2147/CMAR.S250479] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Plate KH, Scholz A, Dumont DJ. Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited. Acta Neuropathol 2012;124:763-75. [PMID: 23143192 DOI: 10.1007/s00401-012-1066-5] [Cited by in Crossref: 140] [Cited by in F6Publishing: 131] [Article Influence: 15.6] [Reference Citation Analysis]
13 Passaro D, Bonnet D. How to say NO to vascular disruption and stem cell mobilization. Expert Opin Ther Targets 2018;22:563-5. [PMID: 29889568 DOI: 10.1080/14728222.2018.1486821] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Vázquez R, Riveiro ME, Berenguer-Daizé C, O'Kane A, Gormley J, Touzelet O, Rezai K, Bekradda M, Ouafik L. Targeting Adrenomedullin in Oncology: A Feasible Strategy With Potential as Much More Than an Alternative Anti-Angiogenic Therapy. Front Oncol 2020;10:589218. [PMID: 33489885 DOI: 10.3389/fonc.2020.589218] [Reference Citation Analysis]
15 Bijou I, Wang J. Evolving trends in pancreatic cancer therapeutic development. Ann Pancreat Cancer 2019;2:17. [PMID: 33089149 DOI: 10.21037/apc.2019.09.01] [Reference Citation Analysis]
16 Zhang Y, Guan XY, Jiang P. Cytokine and Chemokine Signals of T-Cell Exclusion in Tumors. Front Immunol 2020;11:594609. [PMID: 33381115 DOI: 10.3389/fimmu.2020.594609] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
17 Park J, Kim HO, Park KH, Wie MB, Choi SE, Yun JH. A 60% Edible Ethanolic Extract of Ulmus davidiana Inhibits Vascular Endothelial Growth Factor-Induced Angiogenesis. Molecules 2021;26:781. [PMID: 33546250 DOI: 10.3390/molecules26040781] [Reference Citation Analysis]
18 Tsiros D, Sheehy CE, Pecchia S, Nugent MA. Heparin potentiates Avastin-mediated inhibition of VEGF binding to fibronectin and rescues Avastin activity at acidic pH. J Biol Chem 2019;294:17603-11. [PMID: 31601651 DOI: 10.1074/jbc.RA119.009194] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Goblirsch M, Richtig G, Slaby O, Berindan-Neagoe I, Gerger A, Pichler M. MicroRNAs as a tool to aid stratification of colorectal cancer patients and to guide therapy. Pharmacogenomics 2017;18:1027-38. [PMID: 28639472 DOI: 10.2217/pgs-2017-0004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
20 Kim TK, Na HJ, Lee WR, Jeoung MH, Lee S. Heat shock protein 70-1A is a novel angiogenic regulator. Biochem Biophys Res Commun 2016;469:222-8. [PMID: 26657847 DOI: 10.1016/j.bbrc.2015.11.125] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
21 Tien Vo TT, Vo QC, Tuan VP, Wee Y, Cheng HC, Lee IT. The potentials of carbon monoxide-releasing molecules in cancer treatment: An outlook from ROS biology and medicine. Redox Biol 2021;46:102124. [PMID: 34507160 DOI: 10.1016/j.redox.2021.102124] [Reference Citation Analysis]
22 Darragh LB, Oweida AJ, Karam SD. Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment. Front Immunol 2018;9:3154. [PMID: 30766539 DOI: 10.3389/fimmu.2018.03154] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 16.0] [Reference Citation Analysis]
23 Uldry E, Faes S, Demartines N, Dormond O. Fine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer. Int J Mol Sci 2017;18:E1401. [PMID: 28665313 DOI: 10.3390/ijms18071401] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
24 Chatterjee S, Bhattacharjee B. Use of natural molecules as anti-angiogenic inhibitors for vascular endothelial growth factor receptor. Bioinformation 2012;8:1249-54. [PMID: 23275729 DOI: 10.6026/97320630081249] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
25 Lavin DP, Tiwari VK. Unresolved Complexity in the Gene Regulatory Network Underlying EMT. Front Oncol 2020;10:554. [PMID: 32477926 DOI: 10.3389/fonc.2020.00554] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
26 Morales M, Xue X. Targeting iron metabolism in cancer therapy. Theranostics 2021;11:8412-29. [PMID: 34373750 DOI: 10.7150/thno.59092] [Reference Citation Analysis]
27 Scavone C, Sportiello L, Sullo MG, Ferrajolo C, Ruggiero R, Sessa M, Berrino PM, di Mauro G, Berrino L, Rossi F, Rafaniello C, Capuano A; BIO-Cam Group. Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational Study. Front Pharmacol 2017;8:607. [PMID: 28932193 DOI: 10.3389/fphar.2017.00607] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
28 Battisti NML, Decoster L, Williams GR, Kanesvaran R, Wildiers H, Ring A. Targeted Therapies in Older Adults With Solid Tumors. J Clin Oncol 2021;39:2128-37. [PMID: 34043448 DOI: 10.1200/JCO.21.00132] [Reference Citation Analysis]
29 Bucher F, Lee J, Shin S, Kim MS, Oh Y, Ha S, Zhang H, Yea K. Interleukin-5 suppresses Vascular Endothelial Growth Factor-induced angiogenesis through STAT5 signaling. Cytokine 2018;110:397-403. [DOI: 10.1016/j.cyto.2018.06.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
30 Tsai CY, Poon YY, Chan JYH, Chan SHH. Baroreflex functionality in the eye of diffusion tensor imaging. J Physiol 2019;597:41-55. [PMID: 30325020 DOI: 10.1113/JP277008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Gacche RN, Meshram RJ. Angiogenic factors as potential drug target: Efficacy and limitations of anti-angiogenic therapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2014;1846:161-79. [DOI: 10.1016/j.bbcan.2014.05.002] [Cited by in Crossref: 43] [Cited by in F6Publishing: 68] [Article Influence: 6.1] [Reference Citation Analysis]
32 Sridhar SS, Joshua AM, Gregg R, Booth CM, Murray N, Golubovic J, Wang L, Harris P, Chi KN. A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer. Clin Genitourin Cancer 2015;13:124-9. [PMID: 24993934 DOI: 10.1016/j.clgc.2014.06.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
33 Seo JA, Jeon HY, Kim M, Lee YJ, Han ET, Park WS, Hong SH, Kim YM, Ha KS. Anti-metastatic effect of midazolam on melanoma B16F10 cells in the lungs of diabetic mice. Biochem Pharmacol 2020;178:114052. [PMID: 32446885 DOI: 10.1016/j.bcp.2020.114052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Luan X, Gao Y, Guan Y, Xu J, Lu Q, Zhao M, Liu Y, Liu H, Fang C, Chen H. Platycodin D inhibits tumor growth by antiangiogenic activity via blocking VEGFR2-mediated signaling pathway. Toxicology and Applied Pharmacology 2014;281:118-24. [DOI: 10.1016/j.taap.2014.09.009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
35 Cao L, Weetall M, Bombard J, Qi H, Arasu T, Lennox W, Hedrick J, Sheedy J, Risher N, Brooks PC, Trifillis P, Trotta C, Moon YC, Babiak J, Almstead NG, Colacino JM, Davis TW, Peltz SW. Discovery of Novel Small Molecule Inhibitors of VEGF Expression in Tumor Cells Using a Cell-Based High Throughput Screening Platform. PLoS One 2016;11:e0168366. [PMID: 27992500 DOI: 10.1371/journal.pone.0168366] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
36 Gilandoust M, Harsha KB, Mohan CD, Raquib AR, Rangappa S, Pandey V, Lobie PE, Basappa, Rangappa KS. Synthesis, characterization and cytotoxicity studies of 1,2,3-triazoles and 1,2,4-triazolo [1,5-a] pyrimidines in human breast cancer cells. Bioorganic & Medicinal Chemistry Letters 2018;28:2314-9. [DOI: 10.1016/j.bmcl.2018.05.020] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
37 Jeon H, Lee Y, Kim Y, Kim S, Han E, Park WS, Hong S, Kim Y, Ha K. Proinsulin C‐peptide prevents hyperglycemia‐induced vascular leakage and metastasis of melanoma cells in the lungs of diabetic mice. FASEB j 2018;33:750-62. [DOI: 10.1096/fj.201800723r] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
38 Huynh MA, Spektor A. Translational and basic science opportunities in palliative care and radiation oncology. Ann Palliat Med 2019;8:326-36. [PMID: 31370663 DOI: 10.21037/apm.2019.07.08] [Reference Citation Analysis]
39 Huang T, Wang H, Chen NG, Frentzen A, Minev B, Szalay AA. Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy. Mol Ther Oncolytics 2015;2:15003. [PMID: 27119102 DOI: 10.1038/mto.2015.3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
40 Lin YC, Liu CY, Kannagi R, Yang RB. Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis. Arterioscler Thromb Vasc Biol 2018;38:1202-15. [PMID: 29545238 DOI: 10.1161/ATVBAHA.117.310506] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
41 Adelfinger M, Bessler S, Frentzen A, Cecil A, Langbein-Laugwitz J, Gentschev I, Szalay AA. Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy. Viruses 2015;7:4075-92. [PMID: 26205404 DOI: 10.3390/v7072811] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
42 Ai N, Chong CM, Chen W, Hu Z, Su H, Chen G, Lei Wong QW, Ge W. Ponatinib exerts anti-angiogenic effects in the zebrafish and human umbilical vein endothelial cells via blocking VEGFR signaling pathway. Oncotarget 2018;9:31958-70. [PMID: 30174789 DOI: 10.18632/oncotarget.24110] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
43 Welti J, Loges S, Dimmeler S, Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest. 2013;123:3190-3200. [PMID: 23908119 DOI: 10.1172/jci70212] [Cited by in Crossref: 392] [Cited by in F6Publishing: 203] [Article Influence: 49.0] [Reference Citation Analysis]
44 Finley SD, Chu LH, Popel AS. Computational systems biology approaches to anti-angiogenic cancer therapeutics. Drug Discov Today 2015;20:187-97. [PMID: 25286370 DOI: 10.1016/j.drudis.2014.09.026] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 5.1] [Reference Citation Analysis]
45 Singh RK, Nasonkin IO. Limitations and Promise of Retinal Tissue From Human Pluripotent Stem Cells for Developing Therapies of Blindness. Front Cell Neurosci 2020;14:179. [PMID: 33132839 DOI: 10.3389/fncel.2020.00179] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
46 Charpentier MS, Conlon FL. Cellular and molecular mechanisms underlying blood vessel lumen formation. Bioessays 2014;36:251-9. [PMID: 24323945 DOI: 10.1002/bies.201300133] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
47 Pedrosa AR, Trindade A, Carvalho C, Graça J, Carvalho S, Peleteiro MC, Adams RH, Duarte A. Endothelial Jagged1 promotes solid tumor growth through both pro-angiogenic and angiocrine functions. Oncotarget 2015;6:24404-23. [PMID: 26213336 DOI: 10.18632/oncotarget.4380] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
48 Li Z, Kang Y. Emerging therapeutic targets in metastatic progression: A focus on breast cancer. Pharmacol Ther 2016;161:79-96. [PMID: 27000769 DOI: 10.1016/j.pharmthera.2016.03.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
49 Riccardi C, Musumeci D, Platella C, Gaglione R, Arciello A, Montesarchio D. Tuning the Polymorphism of the Anti-VEGF G-rich V7t1 Aptamer by Covalent Dimeric Constructs. Int J Mol Sci 2020;21:E1963. [PMID: 32183039 DOI: 10.3390/ijms21061963] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
50 Fearnley GW, Odell AF, Latham AM, Mughal NA, Bruns AF, Burgoyne NJ, Homer-Vanniasinkam S, Zachary IC, Hollstein MC, Wheatcroft SB, Ponnambalam S. VEGF-A isoforms differentially regulate ATF-2-dependent VCAM-1 gene expression and endothelial-leukocyte interactions. Mol Biol Cell 2014;25:2509-21. [PMID: 24966171 DOI: 10.1091/mbc.E14-05-0962] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
51 He SS, Wang Y, Yang L, Chen HY, Liang SB, Lu LX, Chen Y. Plasma Fibrinogen Correlates with Metastasis and is Associated with Prognosis in Human Nasopharyngeal Carcinoma. J Cancer 2017;8:403-9. [PMID: 28261341 DOI: 10.7150/jca.17028] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
52 Weddell JC, Chen S, Imoukhuede PI. VEGFR1 promotes cell migration and proliferation through PLCγ and PI3K pathways. NPJ Syst Biol Appl 2018;4:1. [PMID: 29263797 DOI: 10.1038/s41540-017-0037-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 6.5] [Reference Citation Analysis]
53 Capasso D, Di Gaetano S, Celentano V, Diana D, Festa L, Di Stasi R, De Rosa L, Fattorusso R, D'Andrea LD. Unveiling a VEGF-mimetic peptide sequence in the IQGAP1 protein. Mol Biosyst 2017;13:1619-29. [PMID: 28685787 DOI: 10.1039/c7mb00190h] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 4.7] [Reference Citation Analysis]
54 Vila Ellis L, Cain MP, Hutchison V, Flodby P, Crandall ED, Borok Z, Zhou B, Ostrin EJ, Wythe JD, Chen J. Epithelial Vegfa Specifies a Distinct Endothelial Population in the Mouse Lung. Dev Cell 2020;52:617-630.e6. [PMID: 32059772 DOI: 10.1016/j.devcel.2020.01.009] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 46.0] [Reference Citation Analysis]
55 Kazemi-lomedasht F, Behdani M, Habibi-anbouhi M, Shahbazzadeh D. Production and Characterization of Novel Camel Single Domain Antibody Targeting Mouse Vascular Endothelial Growth Factor. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 2016;35:167-71. [DOI: 10.1089/mab.2016.0001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
56 Han H, Yang Y, Wu Z, Liu B, Dong L, Deng H, Tian J, Lei H. Capilliposide B blocks VEGF-induced angiogenesis in vitro in primary human retinal microvascular endothelial cells. Biomed Pharmacother 2021;133:110999. [PMID: 33227710 DOI: 10.1016/j.biopha.2020.110999] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Wu Q, Finley SD. Mathematical Model Predicts Effective Strategies to Inhibit VEGF-eNOS Signaling. J Clin Med 2020;9:E1255. [PMID: 32357492 DOI: 10.3390/jcm9051255] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
58 Vargason AM, Anselmo AC, Mitragotri S. The evolution of commercial drug delivery technologies. Nat Biomed Eng 2021. [PMID: 33795852 DOI: 10.1038/s41551-021-00698-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
59 Chatterjee S, Sinha S, Molla S, Hembram KC, Kundu CN. PARP inhibitor Veliparib (ABT-888) enhances the anti-angiogenic potentiality of Curcumin through deregulation of NECTIN-4 in oral cancer: Role of nitric oxide (NO). Cell Signal 2021;80:109902. [PMID: 33373686 DOI: 10.1016/j.cellsig.2020.109902] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
60 Hughes PE, Caenepeel S, Wu LC. Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer. Trends Immunol. 2016;37:462-476. [PMID: 27216414 DOI: 10.1016/j.it.2016.04.010] [Cited by in Crossref: 151] [Cited by in F6Publishing: 143] [Article Influence: 30.2] [Reference Citation Analysis]
61 Ranjan P, Parihar A, Jain S, Kumar N, Dhand C, Murali S, Mishra D, Sanghi SK, Chaurasia J, Srivastava AK, Khan R. Biosensor-based diagnostic approaches for various cellular biomarkers of breast cancer: A comprehensive review. Analytical Biochemistry 2020;610:113996. [DOI: 10.1016/j.ab.2020.113996] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
62 Hamnvik OP, Choueiri TK, Turchin A, McKay RR, Goyal L, Davis M, Kaymakcalan MD, Williams JS. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer 2015;121:311-9. [PMID: 25236375 DOI: 10.1002/cncr.28972] [Cited by in Crossref: 105] [Cited by in F6Publishing: 86] [Article Influence: 15.0] [Reference Citation Analysis]
63 Ganta VC, Annex BH. Peripheral vascular disease: preclinical models and emerging therapeutic targeting of the vascular endothelial growth factor ligand-receptor system. Expert Opin Ther Targets 2021;25:381-91. [PMID: 34098826 DOI: 10.1080/14728222.2021.1940139] [Reference Citation Analysis]
64 De Rosa L, Di Stasi R, D'andrea LD. Pro-angiogenic peptides in biomedicine. Archives of Biochemistry and Biophysics 2018;660:72-86. [DOI: 10.1016/j.abb.2018.10.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
65 Ben-Batalla I, Cubas-Cordova M, Udonta F, Wroblewski M, Waizenegger JS, Janning M, Sawall S, Gensch V, Zhao L, Martinez-Zubiaurre I, Riecken K, Fehse B, Pantel K, Bokemeyer C, Loges S. Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs. Oncotarget 2015;6:6341-58. [PMID: 25849942 DOI: 10.18632/oncotarget.3437] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
66 Yu X, Guo G, Li X, Zhang C, Huang L, Fang D, Song Y, Zhang X, Zhou L. Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival. Medicine (Baltimore) 2015;94:e1361. [PMID: 26313773 DOI: 10.1097/MD.0000000000001361] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
67 Secondini C, Coquoz O, Spagnuolo L, Spinetti T, Peyvandi S, Ciarloni L, Botta F, Bourquin C, Rüegg C. Arginase inhibition suppresses lung metastasis in the 4T1 breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade. Oncoimmunology 2017;6:e1316437. [PMID: 28680747 DOI: 10.1080/2162402X.2017.1316437] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 5.8] [Reference Citation Analysis]
68 Bhattarai P, Hameed S, Dai Z. Recent advances in anti-angiogenic nanomedicines for cancer therapy. Nanoscale 2018;10:5393-423. [DOI: 10.1039/c7nr09612g] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 11.3] [Reference Citation Analysis]
69 Singh RP, Elman MJ, Singh SK, Fung AE, Stoilov I. Advances in the treatment of diabetic retinopathy. J Diabetes Complications 2019;33:107417. [PMID: 31669065 DOI: 10.1016/j.jdiacomp.2019.107417] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
70 Sadasivan C, Zhabyeyev P, Labib D, White JA, Paterson DI, Oudit GY. Cardiovascular toxicity of PI3Kα inhibitors. Clin Sci (Lond) 2020;134:2595-622. [PMID: 33063821 DOI: 10.1042/CS20200302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
71 Li S, van Dijk CGM, Meeldijk J, Kok HM, Blommestein I, Verbakel ALF, Kotte M, Broekhuizen R, Laclé MM, Goldschmeding R, Cheng C, Bovenschen N. Extracellular Granzyme K Modulates Angiogenesis by Regulating Soluble VEGFR1 Release From Endothelial Cells. Front Oncol 2021;11:681967. [PMID: 34178673 DOI: 10.3389/fonc.2021.681967] [Reference Citation Analysis]
72 Granata S, Dalla Gassa A, Carraro A, Brunelli M, Stallone G, Lupo A, Zaza G. Sirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular Effects. Int J Mol Sci 2016;17:E735. [PMID: 27187382 DOI: 10.3390/ijms17050735] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
73 Yeom DH, Lee YS, Ryu I, Lee S, Sung B, Lee HB, Kim D, Ahn JH, Ha E, Choi YS, Lee SH, You WK. ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models. Int J Mol Sci 2020;22:E241. [PMID: 33383646 DOI: 10.3390/ijms22010241] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
74 Tan YF, Lao LL, Xiong GM, Venkatraman S. Controlled-release nanotherapeutics: State of translation. Journal of Controlled Release 2018;284:39-48. [DOI: 10.1016/j.jconrel.2018.06.014] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
75 Lee D, Kim D, Choi YB, Kang K, Sung ES, Ahn JH, Goo J, Yeom DH, Jang HS, Moon KD, Lee SH, You WK. Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis. MAbs 2016;8:892-904. [PMID: 27049350 DOI: 10.1080/19420862.2016.1171432] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 5.6] [Reference Citation Analysis]
76 Shao R, Taylor SL, Oh DS, Schwartz LM. Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization. Oncotarget 2015;6:40507-18. [PMID: 26439689 DOI: 10.18632/oncotarget.5943] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
77 Moccia F, Riccardi C, Musumeci D, Leone S, Oliva R, Petraccone L, Montesarchio D. Insights into the G-rich VEGF-binding aptamer V7t1: when two G-quadruplexes are better than one! Nucleic Acids Res 2019;47:8318-31. [PMID: 31276595 DOI: 10.1093/nar/gkz589] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
78 Tlemsani C, Mir O, Psimaras D, Vano YA, Ducreux M, Escudier B, Rousseau B, Loirat D, Ceccaldi B, André T, Goldwasser F, Ricard D. Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals. Eur J Cancer 2016;66:75-82. [PMID: 27529757 DOI: 10.1016/j.ejca.2016.07.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
79 Schiffmann LM, Brunold M, Liwschitz M, Goede V, Loges S, Wroblewski M, Quaas A, Alakus H, Stippel D, Bruns CJ, Hallek M, Kashkar H, Hacker UT, Coutelle O. A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition. Br J Cancer 2017;116:600-8. [PMID: 28141797 DOI: 10.1038/bjc.2017.13] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
80 Huang SW, Yang HY, Huang WJ, Chen WC, Yu MC, Wang SW, Hsu YF, Hsu MJ. WMJ-S-001, a Novel Aliphatic Hydroxamate-Based Compound, Suppresses Lymphangiogenesis Through p38mapk-p53-survivin Signaling Cascade. Front Oncol 2019;9:1188. [PMID: 31781495 DOI: 10.3389/fonc.2019.01188] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
81 Saman H, Raza SS, Uddin S, Rasul K. Inducing Angiogenesis, a Key Step in Cancer Vascularization, and Treatment Approaches. Cancers (Basel) 2020;12:E1172. [PMID: 32384792 DOI: 10.3390/cancers12051172] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 21.0] [Reference Citation Analysis]
82 Singh SS, Vats S, Chia AY, Tan TZ, Deng S, Ong MS, Arfuso F, Yap CT, Goh BC, Sethi G. Dual role of autophagy in hallmarks of cancer. Oncogene. 2018;37:1142-1158. [PMID: 29255248 DOI: 10.1038/s41388-017-0046-6] [Cited by in Crossref: 201] [Cited by in F6Publishing: 211] [Article Influence: 50.3] [Reference Citation Analysis]
83 Siddharth S, Nayak A, Das S, Nayak D, Panda J, Wyatt MD, Kundu CN. The soluble nectin-4 ecto-domain promotes breast cancer induced angiogenesis via endothelial Integrin-β4. The International Journal of Biochemistry & Cell Biology 2018;102:151-60. [DOI: 10.1016/j.biocel.2018.07.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
84 Small HY, Montezano AC, Rios FJ, Savoia C, Touyz RM. Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome. Can J Cardiol 2014;30:534-43. [PMID: 24786444 DOI: 10.1016/j.cjca.2014.02.011] [Cited by in Crossref: 71] [Cited by in F6Publishing: 57] [Article Influence: 10.1] [Reference Citation Analysis]
85 Guan Y, Liu H, Luan X, Xu J, Lu Q, Liu Y, Gao Y, Zhao M, Chen H, Fang C. Raddeanin A, a triterpenoid saponin isolated from Anemone raddeana, suppresses the angiogenesis and growth of human colorectal tumor by inhibiting VEGFR2 signaling. Phytomedicine 2015;22:103-10. [DOI: 10.1016/j.phymed.2014.11.008] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
86 Trindade A, Duarte A. Notch Signaling Function in the Angiocrine Regulation of Tumor Development. Cells 2020;9:E2467. [PMID: 33198378 DOI: 10.3390/cells9112467] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
87 Choi H, Moon A. Crosstalk between cancer cells and endothelial cells: implications for tumor progression and intervention. Arch Pharm Res 2018;41:711-24. [DOI: 10.1007/s12272-018-1051-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
88 Li G, Lin H, Tian R, Zhao P, Huang Y, Pang X, Zhao L, Cao B. VEGFR-2 Inhibitor Apatinib Hinders Endothelial Cells Progression Triggered by Irradiated Gastric Cancer Cells-derived Exosomes. J Cancer 2018;9:4049-57. [PMID: 30410610 DOI: 10.7150/jca.25370] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
89 Zhou H, Lei PJ, Padera TP. Progression of Metastasis through Lymphatic System. Cells 2021;10:627. [PMID: 33808959 DOI: 10.3390/cells10030627] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Chaudhary S, Singh A, Kumar P, Kaushik M. Strategic targeting of non-small-cell lung cancer utilizing genetic material-based delivery platforms of nanotechnology. J Biochem Mol Toxicol 2021;35:e22784. [PMID: 33826765 DOI: 10.1002/jbt.22784] [Reference Citation Analysis]
91 Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15:385-403. [PMID: 26775688 DOI: 10.1038/nrd.2015.17] [Cited by in Crossref: 406] [Cited by in F6Publishing: 386] [Article Influence: 81.2] [Reference Citation Analysis]
92 Weddell J, Imoukhuede P. Computational Systems Biology for the VEGF Family in Angiogenesis. Encyclopedia of Cardiovascular Research and Medicine. Elsevier; 2018. pp. 659-76. [DOI: 10.1016/b978-0-12-809657-4.99548-6] [Cited by in Crossref: 6] [Article Influence: 2.0] [Reference Citation Analysis]
93 Zhou X, Yue GG, Liu M, Zuo Z, Lee JK, Li M, Tsui SK, Fung KP, Sun H, Pu J, Lau CB. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling. Oncotarget 2016;7:82820-35. [PMID: 27756875 DOI: 10.18632/oncotarget.12652] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
94 Weyergang A, Cheung LH, Rosenblum MG, Mohamedali KA, Peng Q, Waltenberger J, Berg K. Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF121/rGel fusion toxin. Journal of Controlled Release 2014;180:1-9. [DOI: 10.1016/j.jconrel.2014.02.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
95 Xu J, Li Y, Sun X, Zhang D, Liu R, Ziti-Ljajic S, Shi D, Xue F, Le Bail N, Xu R. A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations. Invest New Drugs 2017;35:463-70. [PMID: 28102464 DOI: 10.1007/s10637-016-0421-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
96 Boopathy GTK, Hong W. Role of Hippo Pathway-YAP/TAZ Signaling in Angiogenesis. Front Cell Dev Biol 2019;7:49. [PMID: 31024911 DOI: 10.3389/fcell.2019.00049] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 34.0] [Reference Citation Analysis]
97 Riccardi C, Napolitano E, Platella C, Musumeci D, Melone MAB, Montesarchio D. Anti-VEGF DNA-based aptamers in cancer therapeutics and diagnostics. Med Res Rev 2021;41:464-506. [PMID: 33038031 DOI: 10.1002/med.21737] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
98 Cao Z, Shang B, Zhang G, Miele L, Sarkar FH, Wang Z, Zhou Q. Tumor cell-mediated neovascularization and lymphangiogenesis contrive tumor progression and cancer metastasis. Biochim Biophys Acta 2013;1836:273-86. [PMID: 23933263 DOI: 10.1016/j.bbcan.2013.08.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 37] [Article Influence: 2.4] [Reference Citation Analysis]
99 Cui W, Aouidate A, Wang S, Yu Q, Li Y, Yuan S. Discovering Anti-Cancer Drugs via Computational Methods. Front Pharmacol 2020;11:733. [PMID: 32508653 DOI: 10.3389/fphar.2020.00733] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
100 Gao Z, Song C, Li G, Lin H, Lian X, Zhang N, Cao B. Pyrotinib treatment on HER2-positive gastric cancer cells promotes the released exosomes to enhance endothelial cell progression, which can be counteracted by apatinib. Onco Targets Ther 2019;12:2777-87. [PMID: 31114227 DOI: 10.2147/OTT.S194768] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
101 Di stasi R, Diana D, Capasso D, Di gaetano S, De rosa L, Celentano V, Isernia C, Fattorusso R, D'andrea LD. VEGFR Recognition Interface of a Proangiogenic VEGF-Mimetic Peptide Determined In Vitro and in the Presence of Endothelial Cells by NMR Spectroscopy. Chem Eur J 2018;24:11461-6. [DOI: 10.1002/chem.201802117] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
102 Jang J, Kim MR, Kim TK, Lee WR, Kim JH, Heo K, Lee S. CLEC14a-HSP70-1A interaction regulates HSP70-1A-induced angiogenesis. Sci Rep 2017;7:10666. [PMID: 28878328 DOI: 10.1038/s41598-017-11118-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
103 Lien JC, Chung CL, Huang TF, Chang TC, Chen KC, Gao GY, Hsu MJ, Huang SW. A novel 2-aminobenzimidazole-based compound Jzu 17 exhibits anti-angiogenesis effects by targeting VEGFR-2 signalling. Br J Pharmacol 2019;176:4034-49. [PMID: 31368127 DOI: 10.1111/bph.14813] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
104 Sosa Iglesias V, Giuranno L, Dubois LJ, Theys J, Vooijs M. Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting? Front Oncol 2018;8:267. [PMID: 30087852 DOI: 10.3389/fonc.2018.00267] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 18.0] [Reference Citation Analysis]
105 Vanderborght B, Lefere S, Vlierberghe HV, Devisscher L. The Angiopoietin/Tie2 Pathway in Hepatocellular Carcinoma. Cells 2020;9:E2382. [PMID: 33143149 DOI: 10.3390/cells9112382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
106 Li D, Finley SD. The impact of tumor receptor heterogeneity on the response to anti-angiogenic cancer treatment. Integr Biol (Camb) 2018;10:253-69. [PMID: 29623971 DOI: 10.1039/c8ib00019k] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
107 Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin 2020;70:404-23. [PMID: 32767764 DOI: 10.3322/caac.21631] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 51.0] [Reference Citation Analysis]
108 Jain P, Lee HJ, Qiao W, Wierda W, Benjamini O, Burger J, Ferrajoli A, Estrov Z, Kantarjian H, Keating M, O'Brien S. FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. Cancer 2014;120:3494-501. [PMID: 25043749 DOI: 10.1002/cncr.28910] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
109 Bandookwala M, Sahu AK, Thakkar D, Sharma M, Khairnar A, Sengupta P. Edaravone-caffeine combination for the effective management of rotenone induced Parkinson's disease in rats: An evidence based affirmative from a comparative analysis of behavior and biomarker expression. Neurosci Lett 2019;711:134438. [PMID: 31422100 DOI: 10.1016/j.neulet.2019.134438] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
110 Prasai PK, Shrestha B, Orr AW, Pattillo CB. Decreases in GSH:GSSG activate vascular endothelial growth factor receptor 2 (VEGFR2) in human aortic endothelial cells. Redox Biol. 2018;19:22-27. [PMID: 30096614 DOI: 10.1016/j.redox.2018.07.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
111 Ando H, Asai T, Koide H, Okamoto A, Maeda N, Tomita K, Dewa T, Minamino T, Oku N. Advanced cancer therapy by integrative antitumor actions via systemic administration of miR-499. Journal of Controlled Release 2014;181:32-9. [DOI: 10.1016/j.jconrel.2014.02.019] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
112 Riccardi C, Napolitano E, Musumeci D, Montesarchio D. Dimeric and Multimeric DNA Aptamers for Highly Effective Protein Recognition. Molecules 2020;25:E5227. [PMID: 33182593 DOI: 10.3390/molecules25225227] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
113 Federico SM, Caldwell KJ, McCarville MB, Daryani VM, Stewart CF, Mao S, Wu J, Davidoff AM, Santana VM, Furman WL, Pappo AS, Navid F. Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenib and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumours. Eur J Cancer 2020;132:35-42. [PMID: 32325418 DOI: 10.1016/j.ejca.2020.03.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
114 Mohamedali KA, Cao Y, Cheung LH, Hittelman WN, Rosenblum MG. The functionalized human serine protease granzyme B/VEGF₁₂₁ targets tumor vasculature and ablates tumor growth. Mol Cancer Ther 2013;12:2055-66. [PMID: 23858102 DOI: 10.1158/1535-7163.MCT-13-0165] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
115 Huijbers EJ, van Beijnum JR, Thijssen VL, Sabrkhany S, Nowak-sliwinska P, Griffioen AW. Role of the tumor stroma in resistance to anti-angiogenic therapy. Drug Resistance Updates 2016;25:26-37. [DOI: 10.1016/j.drup.2016.02.002] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 10.2] [Reference Citation Analysis]
116 Oladipupo SS, Kabir AU, Smith C, Choi K, Ornitz DM. Impaired tumor growth and angiogenesis in mice heterozygous for Vegfr2 (Flk1). Sci Rep 2018;8:14724. [PMID: 30283071 DOI: 10.1038/s41598-018-33037-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
117 Semkina AS, Abakumov MA, Skorikov AS, Abakumova TO, Melnikov PA, Grinenko NF, Cherepanov SA, Vishnevskiy DA, Naumenko VA, Ionova KP, Majouga AG, Chekhonin VP. Multimodal doxorubicin loaded magnetic nanoparticles for VEGF targeted theranostics of breast cancer. Nanomedicine 2018;14:1733-42. [PMID: 29730399 DOI: 10.1016/j.nano.2018.04.019] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 9.7] [Reference Citation Analysis]
118 Shi J, Wei PK. Interleukin-8: A potent promoter of angiogenesis in gastric cancer. Oncol Lett 2016;11:1043-50. [PMID: 26893688 DOI: 10.3892/ol.2015.4035] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 7.5] [Reference Citation Analysis]
119 Fahey E, Doyle SL. IL-1 Family Cytokine Regulation of Vascular Permeability and Angiogenesis. Front Immunol 2019;10:1426. [PMID: 31293586 DOI: 10.3389/fimmu.2019.01426] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 25.0] [Reference Citation Analysis]
120 Lai X, Friedman A. How to schedule VEGF and PD-1 inhibitors in combination cancer therapy? BMC Syst Biol 2019;13:30. [PMID: 30894166 DOI: 10.1186/s12918-019-0706-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
121 Janning M, Müller V, Vettorazzi E, Cubas-Cordova M, Gensch V, Ben-Batalla I, Zu Eulenburg C, Schem C, Fasching PA, Schnappauf B, Karn T, Fehm T, Just M, Kühn T, Holms F, Overkamp F, Krabisch P, Rack B, Denkert C, Untch M, Tesch H, Rezai M, Kittel K, Pantel K, Bokemeyer C, Loibl S, von Minckwitz G, Loges S. Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial. Int J Cancer 2019;145:857-68. [PMID: 30694523 DOI: 10.1002/ijc.32163] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
122 Pouyafar A, Heydarabad MZ, Mahboob S, Mokhtarzadeh A, Rahbarghazi R. Angiogenic potential of YKL-40 in the dynamics of tumor niche. Biomed Pharmacother 2018;100:478-85. [PMID: 29477911 DOI: 10.1016/j.biopha.2018.02.050] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
123 Charpentier MS, Tandon P, Trincot CE, Koutleva EK, Conlon FL. A distinct mechanism of vascular lumen formation in Xenopus requires EGFL7. PLoS One 2015;10:e0116086. [PMID: 25705891 DOI: 10.1371/journal.pone.0116086] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]